论文部分内容阅读
自1985年Rubin等发现血清中存在可溶性白细胞介素2受体(sIL-2R)以来,引起了国内外学者的很大兴趣,并进行了广泛的研究。目前对sIL-2R的基础研究已达到了分子水平,临床上大量的研究表明,血清sIL-2R水平与白血病、淋巴系恶性肿瘤、自身免疫性疾病、获得性免疫缺陷综合征、移植排斥、特异性感染等的病情发展与转归呈明显相关。近年来对sIL-2R与恶性实体肿瘤的相关研究也见较多报道,国内报道不多。本文仅就血清sIL-2R在恶性实体肿瘤患者各种情况中的表达及临床意义方面做一综述。
Since Rubin et al. discovered the presence of soluble interleukin 2 receptor (sIL-2R) in serum in 1985, it has attracted great interest from domestic and foreign scholars and has carried out extensive research. At present, the basic research on sIL-2R has reached the molecular level, a large number of clinical studies have shown that serum sIL-2R levels and leukemia, lymphoid malignancies, autoimmune diseases, acquired immunodeficiency syndrome, transplant rejection, specific The development of the disease, such as sexual infection, was significantly related to the outcome. Recent studies on sIL-2R and malignant solid tumors have also been reported. There are few reports in China. This article only summarizes the expression and clinical significance of serum sIL-2R in patients with malignant solid tumors.